Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Metrics to compare | ETON | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipETONPeersSector | |
|---|---|---|---|---|
P/E Ratio | −68.5x | −5.6x | −0.5x | |
PEG Ratio | 3.14 | 0.16 | 0.00 | |
Price/Book | 19.8x | 1.2x | 2.6x | |
Price / LTM Sales | 6.5x | 2.5x | 3.3x | |
Upside (Analyst Target) | 69.9% | 93.1% | 47.1% | |
Fair Value Upside | Unlock | 4.5% | 5.8% | Unlock |